Market research
GTBP GT Biopharma Inc
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 75
- Dividend yield
- Not available
- Beta
- 0.85
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 12M
- P/E ratio
- Not available
- Analyst target
- 75
- Dividend yield
- Not available
- Beta
- 0.85
About
About GT Biopharma Inc
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Research context
GT Biopharma Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the GTBP discussion.
5 years, 7 months ago
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Based on the above factors, GT Biopharma, Inc. Common Stock gets an overall score of 1/5.